|
Index | - | P/E | - | EPS (ttm) | -2.06 | Insider Own | - | Shs Outstand | 32.32M | Perf Week | 0.82% |
Market Cap | 197.20M | Forward P/E | 12.61 | EPS next Y | 0.55 | Insider Trans | - | Shs Float | 26.77M | Perf Month | -64.51% |
Income | -63.60M | PEG | - | EPS next Q | -1.04 | Inst Own | 4.10% | Short Float | 0.07% | Perf Quarter | -73.65% |
Sales | 9.70M | P/S | 20.33 | EPS this Y | 18.10% | Inst Trans | 0.09% | Short Ratio | 1.08 | Perf Half Y | -53.97% |
Book/sh | 8.16 | P/B | 0.85 | EPS next Y | -85.37% | ROA | 51.00% | Target Price | 34.13 | Perf Year | - |
Cash/sh | 10.34 | P/C | 0.67 | EPS next 5Y | - | ROE | 70.10% | 52W Range | 5.92 - 32.04 | Perf YTD | -64.03% |
Dividend | - | P/FCF | 1.89 | EPS past 5Y | - | ROI | -56.00% | 52W High | -79.90% | Beta | - |
Dividend % | - | Quick Ratio | 10.00 | Sales past 5Y | - | Gross Margin | - | 52W Low | 8.78% | ATR | 0.82 |
Employees | 163 | Current Ratio | 10.00 | Sales Q/Q | 1148.40% | Oper. Margin | - | RSI (14) | 17.39 | Volatility | 6.74% 5.54% |
Optionable | No | Debt/Eq | 0.02 | EPS Q/Q | 443.90% | Profit Margin | - | Rel Volume | 2.59 | Prev Close | 6.90 |
Shortable | Yes | LT Debt/Eq | 0.02 | Earnings | - | Payout | 0.00% | Avg Volume | 16.16K | Price | 6.44 |
Recom | 2.00 | SMA20 | -40.13% | SMA50 | -62.74% | SMA200 | -66.69% | Volume | 30,286 | Change | -6.67% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a COVID-19 antiviral therapeutic candidate to inactivate SARS-CoV-2 that is in Phase II clinical trials. The company also develops MP0310, which is in Phase I clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive solid tumors. In addition, it is developing MP0423, a candidate for treating COVID-19 through a single molecule; MP0533, an immune activator for multi-specific treatment of acute myeloid leukemia; and MP0250, a multi-specific DARPin molecule that targets vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Further, the company develops CD3 T-Cell targeting and peptide MHC therapeutic platforms. Molecular Partners AG has strategic partnerships with Allergan, Inc. and Amgen SA for ophthalmology; collaboration with Novartis AG to develop, manufacture, and commercialize DARPin program; and collaboration with AGC Biologics and Baccinex to support development of anti-COVID-19 program. The company was founded in 2004 and is headquartered in Schlieren, Switzerland. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite